Advances and challenges in therapeutic targeting of NRF2
Trends in Pharmacological Sciences · 2023-03 · 44 (3) · 137-149
DOI: 10.1016/j.tips.2022.12.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2023-03. Verfasst von Albena T Dinkova-Kostova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK; Department of Pharmacology and Molecular Sc…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Oxidative Stress, Molecular Targeted Therapy. Die Arbeit wurde bisher 285-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Biotechnology and Biological Sciences Research Council, European Cooperation in Science and Technology.
Abstract (Originalsprache)
Activation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is emerging as an attractive therapeutic approach to counteract oxidative stress, inflammation, and metabolic imbalances. These processes underpin many chronic pathologies with unmet therapeutic needs, including neurodegenerative disorders and metabolic diseases. As the NRF2 field transitions into the clinical phase of its evolution, the need for an understanding of the factors influencing NRF2 pharmacology has never been greater. In this opinion article we describe the rationale for targeting NRF2, summarise the recent advances in drug development of NRF2 modulators, and reflect on the remaining challenges in realising the full clinical potential of NRF2 as a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK; Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of…
- Department of Pharmacology & Therapeutics, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, L69 3GE, UK. Electronic address: ian.copple@liverpool.ac.uk.
Förderung
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
- European Cooperation in Science and Technology
- Medical Research Scotland
Zitieren
APA
Dinkova-Kostova, A. T., & Copple, I. M. (2023). Advances and challenges in therapeutic targeting of NRF2. Trends in Pharmacological Sciences, 44(3), 137-149. https://doi.org/10.1016/j.tips.2022.12.003
Vancouver
Dinkova-Kostova AT, Copple IM. Advances and challenges in therapeutic targeting of NRF2. Trends in Pharmacological Sciences. 2023;44(3):137-149. doi:10.1016/j.tips.2022.12.003
BibTeX
@article{DinkovaKostova2023,
author = {Dinkova-Kostova, Albena T and Copple, Ian M},
title = {Advances and challenges in therapeutic targeting of NRF2},
journal = {Trends in Pharmacological Sciences},
year = {2023},
volume = {44},
number = {3},
pages = {137--149},
doi = {10.1016/j.tips.2022.12.003}
}
EUVIMED